Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...

Title: Biparatopic anti-HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum-refractory ovarian cancer (OC) Presentation Number: 1079P Onsite Poster display date: Saturday, ...

The plan has drawn pushback from the building and real estate industries, along with residents who want to renovate.

At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Rio Claro is a 629-acre planned community in Northwest Fort Worth that was purchased by the Centurion American Development ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...

Tislelizumab addition to CRT improved survival in ESCC, with group B showing a 1-year PFS rate of 73% and OS rate of 85%. The trial's primary endpoint was PFS, with secondary endpoints including OS, ...

A new factor is fueling growth in a number of jobs that don't require a college degree. Here are the roles on the rise.